Abstract:Purpose: To evaluate characteristics of obstructions of the hepatic veins (HVs) in Chinese patients, technical aspects of puncture of the HVs, short- and mid-term outcomes, and complications of endovascular treatment.Patients and Methods: Forty-eight HV patients with different degrees of symptoms and signs of portal hypertension were enrolled in our study. Endovascular treatments with balloon and stents were performed. Catheter-directed thrombolysis (CDT) was performed in patients with thrombosis in the HVs. For patients with lesions of both the HVs and the inferior vena cava (IVC), balloon expansions or stenting were performed at the IVC lesions also.Results: Endovascular treatments were successful in 43 patients. The technically success rate was 89.6% (43/48). Fifteen patients underwent solely balloon expansions, 28 patients had balloon expansions and stentings, 5 patients underwent CDT, and 3 patients had implanted stents in the IVC lesions at the same time. The symptoms of portal hypertension were alleviated in 39 patients postoperatively. In the other 4 cases portal hypertension was mildly alleviated at discharge. Thirty-nine of the 43 patients were followed up for an average of 24 +/- 1.3 months (range, 6-62 months). Ascites were completely resolved in 32 cases, with a small amount of ascites in 4 patients and moderate to massive amounts in 3 patients. Hepatomegaly and splenomegaly completely disappeared in 30 patients and still could be touched in 6 patients. The HVs were patent in 29 patients. Restenosis and re-occlusion of the HVs appeared in 4 cases. All patients were successfully treated by endovascular treatments.Conclusions: Endovascular treatments for patients with obstruction of the HVs have a high technical success rate, fewer complications, and better short- and mid-term clinical outcome. The key to successful endovascular treatment is successful puncture of HVs. For patients who have occlusive lesions of HVs combined with occlusive IVC, recanalization of the lesions of the HVs could achieve good results.

Interventional treatment of hepatocellular carcinoma complicated by Budd-Chiari syndrome

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

Staged Management of Budd-Chiari Syndrome Caused by Co-Obstruction of the Inferior Vena Cava and Main Hepatic Veins.

Imaging Diagnosis and Interventional Treatment for the Primary Hepatocellular Carcinoma with Biliary Obstruction

Interventional Endovascular Treatment for Budd-Chiari Syndrome Using Percutaneous Transluminal Angioplasty and Stents

Interventional and Surgical Treatment of Budd-Chiari Syndrome: A Report of 39 Cases

Interventional or semi-interventional treatment for Budd-Chiari Syndrome

Interventional Treatment of Budd-Chiari Syndrome:Report of 312 Cases

Endovascular treatment of Budd-Chiari syndrome with occlusion of hepatic veins

Interventional Treatment of Hilar Hepatocellular Carcinoma Combined with Obstructive Jaundice

Endovascular Treatment Of Budd-Chiari Syndrome With Hepatic Vein Obstruction In China

The Role of Interventional Treatment on Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombosis

[Progress in Surgical Treatment of Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava].

Evaluation of CT-guided ~(125)I Seed Implantation Combined with Transcatheter Arterial Chemoembolization in Treating Portal Vein Tumor Thrombus Associated with Hepatocellular Carcinoma

Analysis of Surgical Treatment Results in 120 Cases of Budd-Chiari Syndrome

Clinical profile and outcomes of hepatocellular carcinoma in primary Budd-Chiari syndrome

Balloon Angloplasty and Stenting of Hepatic Veins for the Treatment of Budd-Chiari Syndrome Caused by Long Segmental Occlusion of the Inferior Vena Cava (IVC)

Liver transplantation for acute Budd‐Chiari syndrome complicated by portal and inferior vena cava thrombosis

Combined Endovascular Brachytherapy, Sorafenib, and Transarterial Chemobolization Therapy for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus.

Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis